Strides Pharma

{
  "main_header": {
    "sid": 688428,
    "name": "Strides Pharma",
    "stock_name": "Strides Pharma",
    "full_name": "Strides Pharma Science Ltd",
    "name_url": "stocks-analysis/strides-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "863.25",
    "chg": 3.5,
    "chgp": "0.41%",
    "dir": 1,
    "prev_price": "859.75",
    "mcapval": "7,829.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 532531,
    "symbol": "STAR",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE939A01011",
    "curr_date": "Feb 06",
    "curr_time": "",
    "bse_nse_vol": "1.74 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 06, 2026",
    "traded_date_str": "2026 02 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/strides-pharma-688428-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Strides Pharma Science Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/strides-pharma-science-ltd-is-rated-sell-3813976",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/StridesPharmaSc_mojoScore_3813976.png",
        "date": "2026-02-01 10:10:56",
        "description": "Strides Pharma Science Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Strides Pharma Science Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/strides-pharma-science-ltd-valuation-shifts-signal-renewed-price-attractiveness-3813706",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/StridesPharmaSc_valuationdot_3813706.png",
        "date": "2026-02-01 08:03:47",
        "description": "Strides Pharma Science Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, reflecting a recalibration in price attractiveness amid evolving market dynamics. This change, coupled with robust financial metrics and a strong relative performance against benchmarks, invites a closer examination of the company’s current investment appeal within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Strides Pharma Science Ltd Sees Mixed Technical Signals Amid Price Momentum Shift",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/strides-pharma-science-ltd-sees-mixed-technical-signals-amid-price-momentum-shift-3813635",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/StridesPharmaSc_technicaldot_3813635.png",
        "date": "2026-02-01 08:02:37",
        "description": "Strides Pharma Science Ltd has experienced a notable shift in price momentum, reflected in a complex blend of technical indicator signals. Despite a strong intraday rally pushing the stock to ₹908.00, the broader technical landscape remains mixed, with key indicators suggesting a transition from a mildly bearish trend to a more sideways movement. This nuanced technical picture warrants close attention from investors navigating the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Strides Pharma Gains 10.23%: Key Drivers Behind the Weekly Surge",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/strides-pharma-gains-1023-key-drivers-behind-the-weekly-surge-3813015",
        "imagepath": "",
        "date": "2026-01-31 16:02:41",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>27 Jan:</strong> Stock opens at Rs.793.60, down 0.33% amid Sensex gains</p>\n                    <p><strong>28 Jan:</strong> Modest recovery with Rs.796.20 close, Sensex up 1.12%</p>\n                    <p><strong>29 Jan:</strong> Stronger rally to Rs.808.95 (+1.60%) on rising volumes</p>\n                    <p><strong>30 Jan:</strong> Intraday high of Rs.888.80, closes at Rs.877.65 (+8.49%) on record quarterly results</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\">\n                        <div class=\"stat-label\">Week Open</div>\n                        <div class=\"stat-value\">Rs.796.20</div>\n                    </div>\n..."
      },
      {
        "title": "Are Strides Pharma Science Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-strides-pharma-science-ltd-latest-results-good-or-bad-3811871",
        "imagepath": "",
        "date": "2026-01-30 19:21:33",
        "description": "Strides Pharma Science Ltd's latest financial results for Q3 FY26 present a mixed picture of performance. The company reported a consolidated net profit of ₹202.11 crores, reflecting a significant year-on-year growth of 129.80%. This sharp increase is noteworthy, especially when compared to the previous year's profit of ₹87.95 crores. However, the revenue for the same quarter stood at ₹1,194.65 crores, which indicates a modest year-on-year growth of 3.55%, a decline from the previous year's growth rate of 14.71%.\n\nThe operating margin, excluding other income, reached 19.75%, marking the highest level in seven quarters and an improvement from 18.23% in Q3 FY25. This margin expansion suggests enhanced operational efficiency, driven by controlled employee costs and declining interest expenses. However, the company's reliance on exceptional other income, which constituted 42.95% of profit before tax, raises con..."
      },
      {
        "title": "Strides Pharma Science Ltd Reports Very Positive Quarterly Financial Performance Amid Mixed Year-to-Date Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/strides-pharma-science-ltd-reports-very-positive-quarterly-financial-performance-amid-mixed-year-to-date-returns-3811750",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/StridesPharmaSc_fintrenddot_3811750.png",
        "date": "2026-01-30 16:00:08",
        "description": "Strides Pharma Science Ltd has delivered a very positive financial performance in the quarter ended December 2025, marking a significant improvement in key profitability and efficiency metrics. Despite a challenging nine-month period with a decline in profit after tax, the company’s latest quarterly results demonstrate robust operational strength and margin expansion, signalling a potential turnaround in its financial trajectory."
      },
      {
        "title": "Strides Pharma Q3 FY26: Strong Profit Surge Masks Underlying Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/strides-pharma-q3-fy26-strong-profit-surge-masks-underlying-concerns-3811634",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/StridesPharmaSc_quaterlyResult_3811634.png",
        "date": "2026-01-30 14:33:19",
        "description": "Strides Pharma Science Ltd., a mid-sized pharmaceutical company with a market capitalisation of ₹8,058.20 crores, reported a robust 129.80% year-on-year surge in consolidated net profit to ₹202.11 crores for Q3 FY26 (October-December 2025), driven substantially by exceptional other income. However, the stock remains under pressure, trading 14.70% below its 52-week high of ₹1,024.90, as investors grapple with concerns over profit quality and operational sustainability."
      },
      {
        "title": "Strides Pharma Science Ltd Hits Intraday High with 10.42% Surge on 30 Jan 2026",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/strides-pharma-science-ltd-hits-intraday-high-with-1042-surge-on-30-jan-2026-3811578",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/StridesPharmaSc_priceRelatedfactors_3811578.png",
        "date": "2026-01-30 13:31:30",
        "description": "Strides Pharma Science Ltd demonstrated robust intraday performance on 30 Jan 2026, surging 10.42% to touch a day’s high of Rs 888.8, significantly outperforming its sector and the broader market amid volatile trading conditions."
      },
      {
        "title": "When is the next results date for Strides Pharma Science Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-strides-pharma-science-ltd-3806541",
        "imagepath": "",
        "date": "2026-01-27 23:15:47",
        "description": "The next results date for Strides Pharma Science Ltd is scheduled for January 30, 2026...."
      }
    ],
    "total": 640,
    "sid": "688428",
    "stock_news_url": "https://www.marketsmojo.com/news/strides-pharma-science-688428"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)",
      "datetime": "05-Feb-2026",
      "details": "Strides Pharma Inc receives USFDA closure report (EIR) for its formulations facility at Chestnut Ridge New York Inspection included Drug Device Combinations covering our recent filing in Nasal Sprays domain",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "05-Feb-2026",
      "details": "Strides Pharma Inc receives USFDA closure report (EIR) for its formulations facility at Chestnut Ridge New York Inspection included Drug Device Combinations covering our recent filing in Nasa Sprays domain",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "04-Feb-2026",
      "details": "Schedule of Analyst/ Institutional Investors Meet - Intimation under Regulation 30 of SEBI Listing Regulations",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Strides Pharma Science Ltd has declared <strong>40%</strong> dividend, ex-date: 22 Jul 25",
          "dt": "2025-07-22",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Strides Pharma Science Ltd is Rated Sell

2026-02-01 10:10:56

Strides Pharma Science Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Strides Pharma Science Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-02-01 08:03:47

Strides Pharma Science Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, reflecting a recalibration in price attractiveness amid evolving market dynamics. This change, coupled with robust financial metrics and a strong relative performance against benchmarks, invites a closer examination of the company’s current investment appeal within the Pharmaceuticals & Biotechnology sector.

Read full news article

Strides Pharma Science Ltd Sees Mixed Technical Signals Amid Price Momentum Shift

2026-02-01 08:02:37

Strides Pharma Science Ltd has experienced a notable shift in price momentum, reflected in a complex blend of technical indicator signals. Despite a strong intraday rally pushing the stock to ₹908.00, the broader technical landscape remains mixed, with key indicators suggesting a transition from a mildly bearish trend to a more sideways movement. This nuanced technical picture warrants close attention from investors navigating the Pharmaceuticals & Biotechnology sector.

Read full news article

Strides Pharma Gains 10.23%: Key Drivers Behind the Weekly Surge

2026-01-31 16:02:41

Key Events This Week

27 Jan: Stock opens at Rs.793.60, down 0.33% amid Sensex gains

28 Jan: Modest recovery with Rs.796.20 close, Sensex up 1.12%

29 Jan: Stronger rally to Rs.808.95 (+1.60%) on rising volumes

30 Jan: Intraday high of Rs.888.80, closes at Rs.877.65 (+8.49%) on record quarterly results

Week Open

Rs.796.20

...

Read full news article

Are Strides Pharma Science Ltd latest results good or bad?

2026-01-30 19:21:33

Strides Pharma Science Ltd's latest financial results for Q3 FY26 present a mixed picture of performance. The company reported a consolidated net profit of ₹202.11 crores, reflecting a significant year-on-year growth of 129.80%. This sharp increase is noteworthy, especially when compared to the previous year's profit of ₹87.95 crores. However, the revenue for the same quarter stood at ₹1,194.65 crores, which indicates a modest year-on-year growth of 3.55%, a decline from the previous year's growth rate of 14.71%. The operating margin, excluding other income, reached 19.75%, marking the highest level in seven quarters and an improvement from 18.23% in Q3 FY25. This margin expansion suggests enhanced operational efficiency, driven by controlled employee costs and declining interest expenses. However, the company's reliance on exceptional other income, which constituted 42.95% of profit before tax, raises con...

Read full news article

Strides Pharma Science Ltd Reports Very Positive Quarterly Financial Performance Amid Mixed Year-to-Date Returns

2026-01-30 16:00:08

Strides Pharma Science Ltd has delivered a very positive financial performance in the quarter ended December 2025, marking a significant improvement in key profitability and efficiency metrics. Despite a challenging nine-month period with a decline in profit after tax, the company’s latest quarterly results demonstrate robust operational strength and margin expansion, signalling a potential turnaround in its financial trajectory.

Read full news article

Strides Pharma Q3 FY26: Strong Profit Surge Masks Underlying Concerns

2026-01-30 14:33:19

Strides Pharma Science Ltd., a mid-sized pharmaceutical company with a market capitalisation of ₹8,058.20 crores, reported a robust 129.80% year-on-year surge in consolidated net profit to ₹202.11 crores for Q3 FY26 (October-December 2025), driven substantially by exceptional other income. However, the stock remains under pressure, trading 14.70% below its 52-week high of ₹1,024.90, as investors grapple with concerns over profit quality and operational sustainability.

Read full news article

Strides Pharma Science Ltd Hits Intraday High with 10.42% Surge on 30 Jan 2026

2026-01-30 13:31:30

Strides Pharma Science Ltd demonstrated robust intraday performance on 30 Jan 2026, surging 10.42% to touch a day’s high of Rs 888.8, significantly outperforming its sector and the broader market amid volatile trading conditions.

Read full news article

When is the next results date for Strides Pharma Science Ltd?

2026-01-27 23:15:47

The next results date for Strides Pharma Science Ltd is scheduled for January 30, 2026....

Read full news article

View All News